Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Jia, Weihua
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer	Recruiting	3	450	RoW	camrelizumab + famitinib, pembrolizumab, camrelizumab	Jiangsu HengRui Medicine Co., Ltd.	Non-small Cell Lung Cancer	12/23	12/25
NCT06536868: Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC	Recruiting	2	40	RoW	Tislelizumab, Etoposide, Carboplatin or Cisplatin, Thoracic radiotherapy	Second Hospital of Shanxi Medical University	Extensive-stage Small-cell Lung Cancer	07/26	12/26
NCT06570317: Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC	Recruiting	N/A	40	RoW	Nintedanib	Second Hospital of Shanxi Medical University	NSCLC, Nintedanib, Radiation Pneumonitis	05/26	06/26